An Open Label Extension of SKY-0515 in Participants With Huntington's Disease Who Completed a Prior SKY-0515 Treatment Study
Latest Information Update: 27 Apr 2026
At a glance
- Drugs SKY 0515 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
- Sponsors Skyhawk Therapeutics
Most Recent Events
- 24 Apr 2026 Status changed from not yet recruiting to recruiting.
- 23 Apr 2026 New trial record